Clinical Trial Update: Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma

View source ↗

Summary

Expanded access protocol for ELI-002-102 is being offered to patients with KRAS/NRAS-mutated pancreatic ductal adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• ELI-002-102

Snippet

Sponsor: Elicio Therapeutics | Conditions: Pancreatic Ductal Adenocarcinoma, KRAS G12D | Status: AVAILABLE